147 related articles for article (PubMed ID: 35877475)
1. Decreased DNA Damage and Improved p53 Specificity of RITA Analogs.
Zhan Y; Zhou X; Peuget S; Singh M; Peyser BD; Fan Z; Selivanova G
Mol Cancer Ther; 2022 Oct; 21(10):1524-1534. PubMed ID: 35877475
[TBL] [Abstract][Full Text] [Related]
2. Specific RITA Modification Produces Hyperselective Cytotoxicity While Maintaining
Peyser BD; Hermone A; Salamoun JM; Burnett JC; Hollingshead MG; McGrath CF; Gussio R; Wipf P
Mol Cancer Ther; 2019 Oct; 18(10):1765-1774. PubMed ID: 31341033
[TBL] [Abstract][Full Text] [Related]
3. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM
Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis).
Wang Z; Zhang X; Luo Y; Song Y; Xiang C; He Y; Wang K; Yu Y; Wang Z; Peng W; Ding Y; Liu S; Wu C
Cell Death Dis; 2024 May; 15(5):375. PubMed ID: 38811536
[TBL] [Abstract][Full Text] [Related]
5. Chk2 mediates RITA-induced apoptosis.
de Lange J; Verlaan-de Vries M; Teunisse AF; Jochemsen AG
Cell Death Differ; 2012 Jun; 19(6):980-9. PubMed ID: 22158418
[TBL] [Abstract][Full Text] [Related]
6. The p53-reactivating small molecule RITA induces senescence in head and neck cancer cells.
Chuang HC; Yang LP; Fitzgerald AL; Osman A; Woo SH; Myers JN; Skinner HD
PLoS One; 2014; 9(8):e104821. PubMed ID: 25119136
[TBL] [Abstract][Full Text] [Related]
7. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.
Ma T; Yamada S; Ichwan SJ; Iseki S; Ohtani K; Otsu M; Ikeda MA
Biochem Biophys Res Commun; 2012 Jan; 417(3):931-7. PubMed ID: 22166212
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1.
Ahmed A; Yang J; Maya-Mendoza A; Jackson DA; Ashcroft M
Cell Death Dis; 2011 May; 2(5):e160. PubMed ID: 21593792
[TBL] [Abstract][Full Text] [Related]
9. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
[TBL] [Abstract][Full Text] [Related]
10. p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA.
Hedström E; Eriksson S; Zawacka-Pankau J; Arnér ES; Selivanova G
Cell Cycle; 2009 Nov; 8(21):3584-91. PubMed ID: 19838062
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia.
Yang J; Ahmed A; Poon E; Perusinghe N; de Haven Brandon A; Box G; Valenti M; Eccles S; Rouschop K; Wouters B; Ashcroft M
Mol Cell Biol; 2009 Apr; 29(8):2243-53. PubMed ID: 19223463
[TBL] [Abstract][Full Text] [Related]
13. RITA induces apoptosis in p53-null K562 leukemia cells by inhibiting STAT5, Akt, and NF-κB signaling pathways.
Mobaraki RN; Karimi M; Alikarami F; Farhadi E; Amini A; Bashash D; Paridar M; Kokhaei P; Rezvani MR; Kazemi A; Safa M
Anticancer Drugs; 2018 Oct; 29(9):847-853. PubMed ID: 30157040
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
Di Marzo D; Forte IM; Indovina P; Di Gennaro E; Rizzo V; Giorgi F; Mattioli E; Iannuzzi CA; Budillon A; Giordano A; Pentimalli F
Cell Cycle; 2014; 13(4):652-65. PubMed ID: 24345738
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
Forte IM; Indovina P; Iannuzzi CA; Cirillo D; Di Marzo D; Barone D; Capone F; Pentimalli F; Giordano A
Int J Oncol; 2019 Jun; 54(6):2189-2199. PubMed ID: 31081046
[TBL] [Abstract][Full Text] [Related]
16. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38.
Weilbacher A; Gutekunst M; Oren M; Aulitzky WE; van der Kuip H
Cell Death Dis; 2014 Jul; 5(7):e1318. PubMed ID: 25010984
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.
Jones RJ; Bjorklund CC; Baladandayuthapani V; Kuhn DJ; Orlowski RZ
Mol Cancer Ther; 2012 Oct; 11(10):2243-53. PubMed ID: 22933706
[TBL] [Abstract][Full Text] [Related]
18. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
Shin D; Kim EH; Lee J; Roh JL
Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
[TBL] [Abstract][Full Text] [Related]
19. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA.
Zhao CY; Grinkevich VV; Nikulenkov F; Bao W; Selivanova G
Cell Cycle; 2010 May; 9(9):1847-55. PubMed ID: 20436301
[TBL] [Abstract][Full Text] [Related]
20. Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma.
Saha MN; Jiang H; Yang Y; Zhu X; Wang X; Schimmer AD; Qiu L; Chang H
PLoS One; 2012; 7(1):e30215. PubMed ID: 22276160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
